Intestinal mucosal injury induced by tryptase-activated protease-activated receptor 2 requires β-arrestin-2 in vitro

SHUN LI1, JIANQIANG GUAN1*, MIAN GE1, PINJIE HUANG1, YIQUAN LIN2 and XIAOLIANG GAN2

1Department of Anesthesiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510630; 2Department of Anesthesiology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, P.R. China

Received December 26, 2014; Accepted September 1, 2015

DOI: 10.3892/mmr.2015.4325

Abstract. Tryptase exacerbates intestinal ischemia-reperfusion injury, however, the direct role of tryptase in intestinal mucosal injury and the underlying mechanism remains largely unknown. Protease-activated receptor 2 (PAR-2), commonly activated by tryptase, interacts with various adaptor proteins, including β-arrestin-2. The present study aimed to determine whether tryptase is capable of inducing intestinal mucosal cell injury via PAR-2 activation and to define the role of β-arrestin-2 in the process of injury. The IEC-6 rat intestinal epithelial cell line was challenged by tryptase stimulation. Cell viability, lactate dehydrogenase (LDH) activity and apoptosis were analyzed to determine the severity of cell injury. Injury was also evaluated following treatments with specific PAR-2 and extracellular signal-related kinases (ERK) inhibitors, and knockdown of β-arrestin-2. PAR-2, ERK and β-arrestin-2 protein expression levels were evaluated. Tryptase treatment (100 and 1,000 ng/ml) resulted in IEC-6 cell injury, as demonstrated by significant reductions in cell viability, accompanied by concomitant increases in LDH activity and levels of cleaved caspase-3 protein expression. Furthermore, tryptase treatment led to a marked increase in PAR-2 and phosphorylated-ERK expression, and exposure to specific PAR-2 and ERK inhibitors eliminated the changes induced by tryptase. Knockdown of β-arrestin-2 blocked tryptase-mediated cell injury, whereas tryptase exerted no influence on β-arrestin-2 expression in IEC-6 cells. These data indicate that tryptase may directly damage IEC-6 cells via PAR-2 and the downstream activation of ERK, and demonstrate that the signaling pathway requires β-arrestin-2.

Introduction

Mast cells (MCs), containing large quantities of mediators, are widely distributed throughout gastrointestinal tracts (1) and previous studies have demonstrated that MC degranulation may exacerbate injury in a rodent model of small intestinal ischemia-reperfusion (IIR) (2,3). Furthermore, tryptase, uniquely released in MC activation, is important in the process of small IIR injury (2). In addition, tryptase is involved in various types of intestinal disease, such as acute colitis and inflammatory bowel disease (4). However, the role of tryptase in the pathogenesis of small intestinal mucosal injury induced by ischemia has been difficult to define, as oxidative stress and inflammation are involved in vivo (5), and whether tryptase directly induces small intestinal mucosal injury remains to be elucidated.

Protease-activated receptor (PAR) is a family of G protein-coupled receptors that are activated by proteolysis, and thereby act as sensors for extracellular proteases (6). To date, four PARs have been identified, among which PAR-2 is specifically activated by trypsin and MC tryptase, while others are activated by thrombin (7). Various lines of evidence have so far demonstrated that PAR-2, highly expressed in the intestinal epithelial cells, functions in small IIR injury (8) and inhibition of tryptase following ischemia limits this by downregulation of PAR-2 (2). However, the precise mechanism of the direct role of tryptase in small intestinal mucosal injury remains to be elucidated.

β-arrestins (β-arrestin-1 and -2), originally identified as terminators of the G protein-coupled receptorsignaling pathway, interact with PAR-2 as signal scaffolds (9) and a previous study determined that β-arrestins participate in PAR-2-mediated signal transduction (10). As a subtype of the β-arrestin family, Jacob et al (11) demonstrated that β-arrestin-2 is essential for PAR2-induced activation of extracellular signal-related kinase (ERK) 1/2 in colonocytes triggered by tryptase. Furthermore, β-arrestin-2 is significant in PAR-2-stimulated immune cell migration (12) and β-arrestin-2 may negatively regulate inflammation in polymicrobial sepsis (13). However, to the best of our knowledge, no studies have yet elucidated the role...
of β-arrestin-2 in tryptase-induced intestinal mucosal injury under pathophysiological conditions.

Based on previous findings, it was hypothesized that tryptase alone may directly result in small intestinal mucosal injury via PAR-2 activation, and that β-arrestin-2 may participate in the process of injury. This hypothesis was evaluated in the IEC-6 rat intestinal epithelial cell line challenged by tryptase stimulation in the presence or absence of specific PAR-2 and ERK inhibitors, as well by knockdown of β-arrestin-2 in vitro.

Materials and methods

Reagents. IEC-6 cells were purchased from Xiehe Cell Resource Center (Beijing, China). Dulbecco's modified Eagle's medium (DMEM), DMEM with high glucose and fetal bovine serum (FBS) were purchased from Gibco Life Technologies (Carlsbad, CA, USA). Trypsin was obtained from Promega Corporation (Madison, WI, USA). PAR-2 inhibitor, FSLLRY-NH2 (FS) was purchased from Sigma-Aldrich (St. Louis, MO, USA). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay, Cytotoxicity Detection kit and LDH Detection kit were purchased from KeyGen Biotech Co., Ltd. (Nanjing, China). Specific monoclonal antibodies against p44/p42 mitogen-activated protein kinases (MAPK; ERK1/2), phospho (p)-p44/p42 MAPK (p-ERK1/2), total caspase-3, cleaved caspase-3, and MEK1/2 inhibitor, U0126 were purchased from Cell Signaling Technology, Inc., (Beverly, MA, USA). Mouse specific polyclonal antibodies against β-arrestin 2 (mouse/human; dilution, 1:1,000, cat no. ab54790; Abcam, Cambridge, MA, USA) and mouse specific monoclonal antibodies against PAR2 (mouse/rat/human; dilution, 1:500; cat no. sc-13504; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) were used. Furthermore, rabbit monoclonal antibodies against p44/42 (human/mouse/rat; dilution, 1:2,000; cat no. 4695), rabbit monoclonal antibodies against caspase-3 (human/mouse/rat/monkey; dilution, 1:2,000; cat no. 9665), mouse monoclonal antibodies against β-actin (human, mouse, rat; dilution, 1:1,000; cat no. 3700), rabbit monoclonal antibodies against phospho (p)-p44/42 (human/mouse/rat; dilution, 1:2,000; cat no. 8544), rabbit monoclonal antibodies against cleaved caspase-3 (human/mouse/rat/monkey; dilution, 1:2,000; cat no. 9654), horseradish peroxidase (HRP)-conjugated goat anti-mouse immunoglobulin (IgG) (dilution, 1:2,000; cat no. 4410) and HRP-conjugated goat anti-rabbit IgG (dilution, 1:2,000; cat no. 7074) were all purchased from Cell Signaling Technology, Inc., (Beverly, MA, USA). Control small interfering (si)RNA, β-arrestin-2 siRNA and siRNA Transfection Reagent were obtained from Santa Cruz Biotechnology, Inc.

Cell cultures. IEC-6 cells (rat small intestinal epithelial cell line) were cultured in DMEM with 4.5 g/l glucose supplemented with 5% FBS, 0.01 mg/ml insulin, supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin (all from Sigma-Aldrich) in a humidified atmosphere containing 5% CO2 at 37°C. The culture medium was replaced twice each week and all cells used in the experiments were in passage (P)24-P50.

Cell proliferation assay. Cell proliferation was measured by MTT assay, as described previously (14). Cells were collected and seeded at a density of 5,000 cells/well, in 96-well plates, at 37°C in a humid chamber with 5% CO2 for 24 h. The cells were treated with tryptase (0, 10, 100 or 1,000 ng/ml) in medium containing 1% FBS for 0, 6, 12 and 24 h. MTI (1X; 50 µl) was added to each well and incubated with cells at 37°C for 4 h. The medium was replaced with 150 µl dimethyl sulfoxide (DMSO) per well to dissolve the formazan crystals. The optical density (OD) was detected with a ThermoMax microplate reader (Thermo Fisher Scientific, Waltham, MA, USA) at a wavelength of 490 nm. All experiments were performed in triplicate.

β-Arrestin-2 knockdown. The protocol followed that of previous studies with small modifications (15,16). The following solutions were prepared: Solution A, for each transfection, 6 µl siRNA duplex was diluted in 100 µl siRNA transfection medium (reduced-serum medium); Solution B, for each transfection, 6 µl siRNA transfection reagent was diluted in 100 µl siRNA transfection medium. The siRNA duplex solution (solution A) was added directly to the diluted transfection reagent (solution B) using a pipette, mixed gently by repetitive pipetting, and incubated for 30 min at room temperature prior to use. Cells (2x104 per well) were seeded in a 6-well tissue culture plate in 2 ml antibiotic-free normal growth medium supplemented with FBS and incubated at 37°C in a CO2 incubator until the cells were 60-80% confluent. This took 18-24 h. The cells were washed with 2 ml siRNA transfection medium. For each transfection, 0.8 ml siRNA transfection medium was added to each tube containing the siRNA transfection reagent mixture (solution A + solution B). After incubating for 6 h at 37°C in a CO2 incubator, the transfection mixture was removed and replaced with 1X normal growth medium for an additional 24 h, and the cells were subjected to western blot analysis of β-arrestin-2.

Western blot analysis. Cells were scraped and collected in 80 µl lysis buffer (Beyotime Institute of Biotechnology, Haimen, China) per well and maintained at 4°C. Cell lysate was centrifuged at 12,000 x g at 4°C for 15 min and protein concentration in the extracts was determined by bicinchoninic acid assay. Proteins were denatured with loading buffer [30mM EDTA, 36% (v/v) glycerol, 0.05% (w/v) xylene cyanol FF and 0.05% (w/v) bromophenol blue] and separated by 10 or 12% SDS-polyacrylamide gel (Beyotime Institute of Biotechnology) at 200 V for 40 min. Proteins were electro-transferred to 0.22- or 0.44-µm nitrocellulose membranes (Beyotime Institute of Biotechnology) at 100 V for 60 min. The membranes were blocked with 5% non-fat milk dissolved in Tris-bufffered saline with Tween-20 (TBST; pH 7.5, 150 mM NaCl, 10 mM Tris-HCl and 0.1% Tween-20; Beyotime Institute of Biotechnology) at room temperature for 1 h. The membranes
were incubated with different antibodies (anti-ERK, -p-ERK, -PAR-2, -β-arrestin-2, -caspase-3, -cleaved caspase-3 and -β-actin) overnight at 4˚C. The membranes were washed at least three times with TBST and incubated with a horseradish peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG for 1 h at room temperature. Densitometric analyses were performed using Quantity One software v 4.62 (Bio-Rad Laboratories, Hercules, CA, USA).

Statistical analysis. The data are presented as means ± standard error of the mean. Analyses of variance (ANOVA) were performed using Graphpad Prism software v. 5.01 (GraphPad Software, Inc., La Jolla, CA, USA). One-way ANOVA was used for multiple comparisons, followed by the Bonferroni method and Student’s t-test for unpaired values. *P<0.05 was considered to indicate a statistically significant difference.

Results

Tryptase directly induced intestinal epithelial cell injury. A previous study demonstrated that tryptase exacerbated small intestinal injury in a rodent model of IIR (17), however, in vivo results cannot determine the roles of oxidative stress and inflammation in the pathogenesis of small IIR injury (5). Thus, the aim of the present study was to investigate the direct role of tryptase alone in intestinal epithelial cells. As shown in Fig. 1A and B, 100 or 1,000 ng/ml tryptase stimulation for 12 h reduced the cell viabilities of IEC-6 cells, furthermore, incubating IEC-6 cells with 100 or 1,000 ng/ml tryptase exhibited marked injury, as demonstrated by significant increases in LDH activity; however, stimulation with 10 ng/ml tryptase indicated a smaller increase in LDH activity as compared with non-stimulated cells. Furthermore, no statistical differences were observed between the 100 and 1,000 ng/ml groups. These results suggest that tryptase at higher concentrations may directly damage intestinal epithelial cells.

Figure 1. IEC-6 cell injury induced by different concentrations of tryptase stimulation. (A) Cell viabilities measured by MTT assay of IEC-6 cells following tryptase stimulation at different concentrations (0, 1, 10, 100 and 1,000 ng/ml) for 12 h. (B) LDH activity resulting from IEC-6 cells stimulated by different concentrations of tryptase (0, 1, 10, 100, and 1,000 ng/ml) for 8 h. Data are expressed as percentages of the control (non-stimulated) group (n=4). **P<0.01, ***P<0.005 vs. control group. LDH, lactate dehydrogenase.

Figure 2. Time-course changes in PAR-2 protein expression in IEC-6 cells following tryptase stimulation at different time-points (0, 2, 12 and 24 h). (A) Band of PAR-2 protein expression in IEC-6. (B) Quantification of PAR-2 protein expression in IEC-6 cells (n=3). *P<0.05 vs. control (non-stimulated) group. PAR-2, protease-activated receptor 2.
IEC-6 cell injury was induced by tryptase via PAR-2. As tryptase may upregulate PAR-2 protein expression, the current study evaluated whether tryptase mediates IEC-6 cell injury via the PAR-2 signaling pathway. Thus, a specific PAR-2 inhibitor, FS, was employed. Treatment with 200 or 400 µM FS blocked significant increases in LDH activity and cleaved caspase-3 protein expression when challenged by 1,000 ng/ml tryptase stimulation. Furthermore, FS alone at concentrations of 200 and 400 µM had no effect on LDH activity, as compared with the control group. In addition, no significant differences between FS at concentrations of 200 and 400 µM were identified (P>0.05; Fig. 3A).

ERK-2 was involved in the PAR-2 signaling pathway. As MAPK is one of the downstream signal pathways of PAR-2, the current study examined the role of ERK, an MAPK. The results demonstrated that p-ERK protein expression was significantly increased and peaked 30 min subsequent to tryptase (1,000 ng/ml) exposure; however, p-ERK protein expression was reduced to baseline at 60-90 min. Furthermore, as shown in Fig. 4, the specific ERK inhibitor (U0126) blocked tryptase-mediated IEC-6 cell injury, as demonstrated by markedly downregulating LDH activity.

Role of β-arrestin-2 in tryptase-mediated IEC-6 cell injury. Previous studies have demonstrated that β-arrestin-2 is involved in PAR-2-associated signaling pathways, and affects the structure and function of cells (10). In the present study, the β-arrestin-2 protein expression exhibited no changes within 24 h of 1,000 ng/ml tryptase stimulation. Following knockdown of β-arrestin-2 (Fig. 5C and D), the IEC-6 cell injury was significantly attenuated, as demonstrated by a marked reduction in LDH activity, and the cleaved caspase-3 protein expression when compared with the control groups in the presence of 100-1,000 ng/ml tryptase (Fig. 5E-G). Additionally, after 12 h exposure to 1,000 ng/ml tryptase, β-arrestin-2 knockdown significantly reduced the increases in PAR-2 protein expression that were induced by tryptase (Fig. 5H and I). These results collectively indicate that tryptase-mediated IEC-6 cell injury via PAR-2 activity requires β-arrestin-2.

Discussion

Our previous study indicated that tryptase may aggravate small IIR injury (2), however, little is known of the direct role of tryptase in small intestinal epithelial cells. In the present study, tryptase alone was demonstrated to directly induce IEC-6 cell injury, as demonstrated by significant increases in LDH activity and cleaved caspase-3 protein expression following exposure to 100 or 1,000 ng/ml tryptase for 12 h. Furthermore, tryptase markedly upregulated PAR-2 expression and specifically inhibiting PAR-2 significantly abrogated tryptase-mediated injury. Furthermore, ERK was demonstrated to be involved in the process of injury, as the addition of an ERK inhibitor blocked the increase in LDH activity, which had been induced by tryptase. Notably, tryptase stimulation exerted no effects on β-arrestin-2 protein expression.
on the expression of β-arrestin-2 in IEC-6 cells whereas the injury induced by tryptase was significantly reduced following β-arrestin-2 knockdown. These results suggest that tryptase may directly result in IEC-6 cell injury by activating the PAR-2/ERK signaling pathway, and that the process of tryptase-mediated injury requires β-arrestin-2.

Tryptase is a protease that is released by MCs and accounts for >25% of the total MC protein (19). Tryptase has been demonstrated to contribute to various disorders; for example, tryptase was demonstrated to be key in the development of airway hyperresponsiveness in a mouse model of asthma (20). Furthermore, tryptase contributes to colitis, as stabilizing MCs, by releasing tryptase, significantly alleviate the symptoms of colitis (21). A previous study suggests that tryptase levels in the lower gastrointestinal tract were 33.5 ng/mg (range, 8.0-154.6 ng/mg), and the tissue tryptase concentrations were significantly increased to 55.7 ng/mg (range, 9.3-525.0) subsequent to MC degranulation (22), thus, a range from 1 to 1,000 ng/ml tryptase was used in the current study. The direct mechanism by which tryptase alone contributes to IEC-6 cell injury was assessed in the present study. It was identified that 100 or 1,000 ng/ml tryptase stimulation resulted in significant damages to IEC-6 cells, which is consistent with a previous report demonstrating that tryptase significantly contributes to inflammatory bowel disease (4). The findings from the present study further confirm that tryptase released by MC activation is critical in small intestinal mucosal cell injury.

PAR-2 is highly expressed in small intestinal mucosa, our previous studies have demonstrated that inhibiting tryptase may reduce small IIR injury with associated downregulation of PAR-2 (17), furthermore, tryptase-induced itch occurs via activation of PAR-2 (23). However, since PAR-2 may be activated by various factors, including tryptase and trypsin, it is unknown whether the changes in PAR-2 are directly triggered by tryptase released from MC degranulation during IIR injury in vivo. In the present in vitro study, tryptase stimulation was indicated to induce significant increases in PAR-2 protein expression and, furthermore, the PAR-2 inhibitor, FS blocked the damage to IEC-6 cells, which had been triggered by 100 or 1,000 ng/ml tryptase. The results indicate that tryptase-mediated intestinal mucosal injury is via the PAR-2 signaling pathway.

The activation of PAR-2 initiates multiple inflammatory responses (24), and PAR-2 activation often leads to subsequent activation of downstream MAPK signaling pathways (7), Groschwitz et al (25) demonstrated that chymase stimulation of Caco-2 BBecells resulted in a significant increase in p38 and p44/p42 (ERK1/2) activity at 15 and 60 min and, furthermore, that those changes were PAR-2-dependent. In the present study it was found that p-ERK expression was significantly increased and peaked at 30 min after tryptase stimulation, and the addition of a specific ERK inhibitor reduced the significant tryptase-induced elevations in LDH activity and cleaved caspase-3 protein expression in IEC-6 cells. The findings from the current study suggest tryptase may injure IEC-6 cells via PAR-2 activation and the downstream ERK signaling pathway.

β-arrestin-2 is an adaptor protein that may promote desensitization of G-protein signaling, it also functions as a scaffold protein in the process of PAR-2 activation (26), and this signaling pathway is crucial for PAR-2-stimulated cell migration (10). However, the role of β-arrestin-2 in tryptase-mediated IEC-6 cell injury remains to be elucidated. In the present study, the results demonstrate that there were no changes in β-arrestin-2 protein expression resulting from tryptase stimulation; however, the tryptase-mediated IEC-6 cell injury, as well as upregulation in PAR-2 protein expression, was blocked.
Let al: TRYPTASE-MEDIATED INTESTINAL INJURY REQUIRES β-ARRESTIN-2. These results are consistent with reports that the PAR-2-mediated inflammatory process in the airway is β-arrestin-2-dependent (27). The findings from the current study further suggest that β-arrestin-2 functions as a scaffold/adaptor protein for PAR-2 activation triggered by tryptase stimulation.

There are certain limitations of the present study; firstly, four PARs are expressed in small intestinal mucosal cells, and the current study did not examine the roles of PAR-1, -3, or -4 in IEC-6 cell injury, as a previous study demonstrated that PAR-2 is specifically activated by tryptase. Secondly, the downstream MAPK signaling pathways induced by β-arrestin-2 knockdown. These results are consistent with reports that the PAR-2-mediated inflammatory process in the airway is β-arrestin-2-dependent (27). The findings from the current study further suggest that β-arrestin-2 functions as a scaffold/adaptor protein for PAR-2 activation triggered by tryptase stimulation.

There are certain limitations of the present study; firstly, four PARs are expressed in small intestinal mucosal cells, and the current study did not examine the roles of PAR-1, -3, or -4 in IEC-6 cell injury, as a previous study demonstrated that PAR-2 is specifically activated by tryptase. Secondly, the downstream MAPK signaling pathways induced by
PAR-2 activation include ERK1/2, c-Jun N-terminal kinase and p38 kinases. However, only ERK1/2 was analyzed in the present study, as these kinases share the same signaling pathways (28).

In conclusion, these data suggest that tryptase alone may induce IEC-6 cell injury, via the PAR-2 and ERK signaling pathways. Furthermore, the activation of PAR-2, which is triggered by tryptase requires β-arrestin-2.

Acknowledgements

The present study was supported by the Fundamental Research Funds for the Central Universities of China (grant no. 12ykpy37) and Science and Technology Program of Guangzhou, China (grant no. 2014J4100172).

References
